

**FIXED-DOSE COMBINATIONS
FOR HIV/AIDS,
TUBERCULOSIS, AND
MALARIA**

**Report of a meeting held
16-18 December 2003
Geneva**



World Health Organization
Geneva

Contents

Summary: Observations and some ways forward.....	1
A. Overall observations	1
B. Experiences with fixed-dose combinations	2
C. Public health priorities	4
D. IP and legal options	5
E. Pharmaceutical development, quality assurance, and regulatory requirements	7
Welcome.....	9
Objectives of the meeting	10
Expected outcomes.....	10
Presentations on TB FDC issues	11
Presentations and discussions on malaria FDC issues.....	12
Presentations and discussions concerning ARV FDCs	14
Presentation and discussion of cross-cutting issues related to logistics, adherence and resistance with FDCs	17
Procurement experiences	19
Intellectual property and industry issues	20
Regulatory issues	22
Concluding session	24
Fixed-dose combinations for tuberculosis: lessons learned from a clinical, formulation and regulatory perspective	29
Abstract.....	30
Tuberculosis in the world of today	30
Combination therapy and fixed-dose combination (FDC) formulations in the management of TB	35
Continuation Phase.....	40
Registration requirements for rifampicin-containing FDC formulations.....	45
Conclusions.....	46
Acknowledgments	47
Annex: Bioavailability of rifampicin, the Biopharmaceutic Classification System and the 4D approach to disease management.....	48
Results/c results/comments.....	53
References.....	63
Product costs of fixed-dose combination tablets in comparison with separate dispensing and or co-blistering of antituberculosis drugs.....	67
Introduction	67
Method.....	68
Results.....	69
Discussion	70
References:.....	75

Fixed-dose combinations: artemisinin-based combination therapies for malaria treatment	77
Introduction	77
Background	78
Implementation issues	82
Process leading to the development of guidelines on the use of artemisinin-based combination therapies (ACTs).....	85
Support to countries in the implementation of ACTs	87
Challenges/way forward	88
Recommendations for further research.....	89
Conclusion.....	89
References.....	90
Developing combinations of drugs for malaria examination of critical issues and lessons learnt	91
Background	91
Parasite resistance to antimalarial drugs: a major impediment to effective control	92
Strategies to overcome resistance.....	92
Evidence – the key to sensible recommendations.....	93
Further work on the artemisinins	95
Recommendations & outstanding challenges	96
References.....	97
Safety and long-term effectiveness of generic fixed-dose formulations of nevirapine-based HAART amongst antiretroviral-naïve HIV-infected patients in India	99
Abstract.....	99
Introduction	100
Methods	104
Results.....	106
Discussion	109
Immunological improvement.....	110
Viral load	110
Clinical findings	110
Conclusions	111
References.....	112
Effect of introduction of fixed-dose combinations on the drug supply chain: experiences from the field	113
Abstract.....	113
Intoduction.....	113
Procurement.....	114
Distribution	115
Prescribing.....	116
Dispensing to patients	116
Cost to patient.....	116
Patient use	117
Consumption data.....	117
Conclusion.....	118
References.....	118

Effect of fixed-dose combination (FDC) medications on adherence and treatment outcomes	119
Introduction	119
Evidence of effect of FDCs or unit-of-use packaging on adherence and treatment outcomes.....	121
Research needs.....	124
Conclusion.....	126
Acknowledgements	131
References:.....	132
Effect of fixed-dose combination (FDC) drugs on development of clinical antimicrobial resistance: a review paper.....	135
Executive summary.....	135
Introduction	137
Biological basis for drug resistance to anti-TB, HIV/AIDS and malaria drugs.....	138
Combination drugs in the context of AMR.....	140
Overcoming clinical resistance using combinations: what is the evidence?	143
Future research needs.....	145
Conclusion.....	146
Selected studies comparing combinations, FDCs, blister packs and monotherapy with regard to development of antimicrobial resistance	147
References.....	151
Fixed-dose combination (FDC) drugs availability and use as a global public health necessity : intellectual property and other legal issues.....	155
Executive summary.....	155
Introduction	156
IPRs and Fixed-dose Combinations: Introduction to the “Anticommons Problem”	157
IPRs and Fixed-dose Combinations: The “Anticommons Problem” (II)	158
Overcoming IP/Legal barriers	160
Back to the Future: TRIPS, Public Health, Access to Medicines	163
Recommendations.....	165
Conclusions.....	166
References.....	167
Pharmaceutical development and quality assurance of FDCs.....	169
Abstract.....	169
Introduction	170
Preformulation studies	171
Some examples of the relevance of the properties of the API to product formulation! ...	174
Good Manufacturing Practice (GMP).....	176
Issues that may arise in the formulation of FDCs that do not arise for single entity products include:.....	176
Changes to registered products (variations)	177
Quality control of FDCs.....	178
Recommendations.....	180
References.....	180
Annotated agenda	183
List of participants	189